⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EBS News
Emergent Biosolutions, Inc.
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy
globenewswire.com
EBS
$94 Bn Vaccines Market Industry Trends and Global Forecasts, 2026-2035: 200+ Preventive Vaccines, Developed by Both Industry and Non-industry Players are Being Evaluated
globenewswire.com
EBS
NVAX
MRNA
PFE
Emergent BioSolutions to Participate in Upcoming Investor Conferences
globenewswire.com
EBS
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]
globenewswire.com
EBS
NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
accessnewswire.com
NNVC
SIGA
EBS
GILD
Form 8-K
sec.gov
EBS
Emergent BioSolutions Reports First Quarter 2026 Financial Results
globenewswire.com
EBS
Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox
globenewswire.com
EBS
Form 8-K
sec.gov
EBS
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142
globenewswire.com
SABS
EBS